Univariate Cox analysis identified age (>60 years), advanced clinical stage (III-IV), high IPI score (3-5), hypoalbuminemia, presence of extranodal sites (≥2), elevated LDH, non-GCB phenotype, MYC+/BCL-2+ double-expressing phenotype, and the expression of VSIG4 as adverse prognosis factors, while rituximab as a protective factor. This evidence concerns the gene MYC and Hypoalbuminemia.